Abbott to spin off Nutrition business into independent public company by end of 2027
+1 new source since this summary was written
Abbott announced it will separate its Nutrition unit into a stand‑alone, publicly traded company slated for completion by the end of 2027. The new entity will generate roughly $8.5 billion in annual sales and will be led by Daniel Salvadori, who will become its chief executive officer. Abbott expects the split to be tax‑free for shareholders, will incur one‑time transaction costs, and will retain about $42 billion in sales focused on medical devices, diagnostics and pharmaceuticals.
Why it matters
Shareholders will receive shares in both Abbott and the new Nutrition company, creating a distinct investment opportunity for each business (the company’s note says the dividend will be paid by both entities at the same level). Abbott’s remaining operations will concentrate on higher‑growth medical‑device and diagnostics markets, potentially improving growth and margin profiles for the parent company.
Key facts
- 1Abbott plans to complete the Nutrition spin‑off by the end of 2027. prnewswire.com
- 2The Nutrition business is expected to have approximately $8.5 billion in annual sales. prnewswire.com
- 3Abbott’s post‑separation sales are projected to be about $42 billion. prnewswire.com
- 4Daniel Salvadori will become chief executive officer of the new Nutrition company. prnewswire.com
- 5The separation will be executed as a tax‑free distribution to Abbott shareholders. prnewswire.com
- 6Abbott expects to incur one‑time charges related to the transaction, amount to be quantified later. prnewswire.com
Summary written by AlphAI AI Desk from 20 of 21 sources. Not investment advice. Figures are as stated by the linked sources.